# US 2008/0076732 A1 · Gene expression control DNA element and associated protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0076732 A1
- Document ID: US20080076732A1
- Status: Published application
- Kind: A1
- Application number: 11/973,835
- Filed: 2007-10-09
- Published: 2008-03-27
- Earliest claimed: 2000-09-30
- Assignees: Elizabeth K. Barber
- Inventors: Elizabeth Barber
- Web page: https://patentgrep.com/patent/US20080076732A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/4708: {Duchenne dystrophy}
- C07K 16/3061: {Blood cells}
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Through screening of an expression library, a cDNA sequence has been identified that encodes a protein that interacts with human CD33, the DNA being highly homologous to a portion of the human dystrophin gene. A region of that cDNA has been identified as an important regulatory element in controlling expression, both transcription and translation, of the DNA with which it is associated. This DNA sequence element may be used as a regulatory cassette in conjunction with any suitable gene, to modify gene expression. The putative controlling DNA sequence element contains a minimum of 137 base pairs (FIG. 1) to 147 base pairs (FIG. 1A) and a maximum of 287 base pairs (FIG. 1B).

## Claims

### Claim at position 1

-18. (canceled)

### Claim 19

A protein or polypeptide encoded by a polynucleotide comprising SEQ ID NO: 1.

### Claim 20 (depends on 19)

The protein or polypeptide of claim 19 that is expressed on a cell surface in vivo.

### Claim 21 (depends on 19)

The protein or polypeptide of claim 19 that binds to the human CD33 protein.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The protein or polypeptide of claim 1, that is encoded by a polynucleotide comprising the DNA sequence of SEQ ID NO: 2.

### Claim 25 (depends on 24)

The protein or polypeptide of claim 24, that binds to the human CD33 protein.

### Claim 26 (depends on 24)

The protein or polypeptide of claim 24 that is expressed on a cell surface in vivo.

### Claim 27 (depends on 26)

The protein or polypeptide of claim 26, wherein the protein or polypeptide is homologous to a portion of human dystrophin that is expressed on the cell surface in vivo.

### Claim 28 (depends on 24)

The protein or polypeptide of claim 24 having a molecular weight of substantially 50, 40 or 25 Kd, obtainable by expression of the polynucleotide of SEQ ID NO: 2.

### Claim 29 (depends on 28)

The protein or polypeptide of claim 28 having the sequence MYPIMEYSCSDRN; YIYIGNLNVADTM; or DDLGRAMESLVSVMTDEE.

### Claim 30 (depends on 24)

The protein or polypeptide of claim 24, wherein the protein is a heterodimer.

### Claim 31 (depends on 24)

The protein or polypeptide of claim 24 that is expressed in one or more of the group of tissues consisting of leucocytes, brain, muscle and placenta.

### Claim 32 (depends on 19)

An antibody specific for the protein or polypeptide of claim 19.

### Claim 33 (depends on 24)

An antibody specific for the protein or polypeptide of claim 24.

### Claim 34 (depends on 1, 19, 24)

A method of screening for leukemic cells and associated disease states such as leukemia, comprising analyzing DNA of cells to detect the presence of the polynucleotide of claim 1; analyzing DNA of cells to detect the presence of SEQ ID NO: 1; analyzing DNA of cells to detect the presence of SEQ ID NO: 2; analyzing protein of cells to detect the presence of the protein or polypeptide of claim 19; or analyzing protein of cells to detect the presence of the protein or polypeptide of claim 24.

### Claim 35 (depends on 19, 34)

The method of claim 34, wherein protein is detected using an antibody specific for a protein or polypeptide of claim 19.

### Claim 36 (depends on 24, 34)

The method of claim 34, wherein protein is detected using an antibody specific for a protein or polypeptide of claim 24.

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

A method of gene therapy comprising treating an affected individual with an effective amount of a polynucleotide comprising SEQ ID NO: 1.

### Claim 40

A method of treating an individual affected by a disorder in which protein truncation plays a part, comprising delivery of an amount of a polynucleotide effective to treat the disorder, wherein the polynucleotide comprising SEQ ID NO: 1.
